|
AUPO755097A0
(en)
*
|
1997-06-25 |
1997-07-17 |
University Of Queensland, The |
Receptor agonist and antagonist
|
|
AUPQ339899A0
(en)
|
1999-10-13 |
1999-11-04 |
University Of Queensland, The |
Novel molecules
|
|
CA2418652C
(en)
|
2000-08-10 |
2010-03-23 |
Mitsubishi Pharma Corporation |
Novel 3-substituted urea derivatives and medicinal use thereof
|
|
US7855297B2
(en)
|
2000-09-14 |
2010-12-21 |
Mitsubishi Tanabe Pharma Corporation |
Amide derivatives and medicinal use thereof
|
|
AUPR833401A0
(en)
*
|
2001-10-17 |
2001-11-08 |
University Of Queensland, The |
G protein-coupled receptor antagonists
|
|
JP4290564B2
(ja)
|
2002-03-19 |
2009-07-08 |
チルドレンズ ホスピタル メディカル センター |
Ｃ５ａアナフィラトキシンの突然変異タンパク質、このような突然変異タンパク質をコードする核酸分子ならびにＣ５ａアナフィラトキシンの突然変異タンパク質の医薬的使用
|
|
WO2003084524A1
(en)
*
|
2002-03-29 |
2003-10-16 |
Neurogen Corporation |
Combination therapy for the treatment of conditions with pathogenic inflammatory components
|
|
AUPS160602A0
(en)
*
|
2002-04-08 |
2002-05-16 |
University Of Queensland, The |
Therapeutic method
|
|
AU2002950657A0
(en)
|
2002-08-08 |
2002-09-12 |
Alchemia Limited |
Derivatives of monosaccharides for drug discovery
|
|
AU2002951995A0
(en)
|
2002-10-11 |
2002-10-31 |
Alchemia Limited |
Classes of compounds that interact with gpcrs
|
|
AU2003266858B2
(en)
*
|
2002-10-11 |
2006-09-14 |
Vast Bioscience Pty Limited |
Classes of compounds that interact with GPCRs
|
|
AU2002952086A0
(en)
*
|
2002-10-16 |
2002-11-07 |
The University Of Queensland |
Treatment of osteoarthritis
|
|
US7410945B2
(en)
*
|
2002-10-16 |
2008-08-12 |
The University Of Queensland |
Treatment of inflammatory bowel disease
|
|
AU2002952129A0
(en)
*
|
2002-10-17 |
2002-10-31 |
The University Of Queensland |
Treatment of hypersensitivity conditions
|
|
AU2003902354A0
(en)
*
|
2003-05-15 |
2003-05-29 |
Harkin, Denis W. |
Treatment of haemorrhagic shock
|
|
AU2003902586A0
(en)
*
|
2003-05-26 |
2003-06-12 |
The University Of Queensland |
Treatment of burns
|
|
WO2005014849A2
(en)
*
|
2003-07-03 |
2005-02-17 |
Euro-Celtique, S.A. |
Genes associated with responses to neuropathic pain
|
|
EP1498422A1
(de)
*
|
2003-07-17 |
2005-01-19 |
Jerini AG |
C5a-Rezeptor-Antagonisten
|
|
CA2579678A1
(en)
*
|
2004-10-04 |
2006-04-13 |
Alchemia Limited |
Selective inhibitors
|
|
CN101107264A
(zh)
*
|
2005-01-17 |
2008-01-16 |
捷瑞尼股份公司 |
C5a受体拮抗剂
|
|
AU2006223108A1
(en)
*
|
2005-03-11 |
2006-09-21 |
Potentia Pharmaceuticals, Inc. |
Compositions comprising modulators of G-protein-coupled receptor for treatment of macular degeneration
|
|
EP1739078A1
(de)
|
2005-05-30 |
2007-01-03 |
Jerini AG |
C5a-Rezeptor-Antagonisten
|
|
US20070292421A1
(en)
*
|
2005-07-28 |
2007-12-20 |
Feinberg Bruce B |
Method for treating preeclampsia
|
|
US8168584B2
(en)
|
2005-10-08 |
2012-05-01 |
Potentia Pharmaceuticals, Inc. |
Methods of treating age-related macular degeneration by compstatin and analogs thereof
|
|
PL2148691T3
(pl)
|
2007-02-05 |
2015-12-31 |
Apellis Pharmaceuticals Inc |
Analogi kompstatyny do stosowania w leczeniu stanów zapalnych układu oddechowego
|
|
WO2009015087A2
(en)
*
|
2007-07-20 |
2009-01-29 |
Potentia Pharmaceuticals, Inc. |
Compositions and methods for treatment of trauma
|
|
EP2278987A4
(en)
*
|
2008-03-28 |
2012-08-22 |
Apellis Ag |
MODULATION AND REPLY / IMPROVEMENT OF THE COMPLEMENTARY SYSTEM IN THE TREATMENT OF TRAUMATISM
|
|
US20100000605A1
(en)
*
|
2008-07-02 |
2010-01-07 |
Saint-Gobain Performance Plastics Chaineux |
Framed device, seal, and method for manufacturing same
|
|
LT2894165T
(lt)
|
2008-11-10 |
2023-03-10 |
Alexion Pharmaceuticals, Inc. |
Būdai ir kompozicijos, skirti su komplementu susijusių sutrikimų gydymui
|
|
AU2011207441A1
(en)
*
|
2010-01-22 |
2012-08-09 |
The Trustees Of The University Of Pennsylvania |
Methods of treating or preventing periodontitis and diseases associated with periodontitis
|
|
EP2824111B1
(en)
|
2010-04-30 |
2017-03-22 |
Alexion Pharmaceuticals, Inc. |
Anti-C5A Antibodies and Methods for Using the Antibodies
|
|
AU2011276445A1
(en)
|
2010-06-29 |
2013-02-21 |
Board Of Regents Of The University Of Nebraska |
Analogs of C5a and methods of using same
|
|
EP2468295A1
(en)
*
|
2010-12-21 |
2012-06-27 |
Affiris AG |
Vaccines based on peptides of the complement protein C5a
|
|
CN103796667A
(zh)
|
2011-06-22 |
2014-05-14 |
艾普莱斯制药公司 |
用补体抑制剂治疗慢性障碍的方法
|
|
US9289467B2
(en)
|
2011-08-10 |
2016-03-22 |
Case Western Reserve University |
Compositions and methods for treating bone conditions
|
|
US20150241429A1
(en)
*
|
2012-09-11 |
2015-08-27 |
Hospital For Special Surgery |
Irhom2 inhibition for the treatment of complement mediated disorders
|
|
ES2879430T3
(es)
|
2012-11-15 |
2021-11-22 |
Apellis Pharmaceuticals Inc |
Análogos de compstatina de acción prolongada y composiciones y métodos relacionados
|
|
WO2014152391A1
(en)
|
2013-03-15 |
2014-09-25 |
Apellis Pharmaceuticals, Inc. |
Cell-penetrating compstatin analogs and uses thereof
|
|
CA2908552A1
(en)
*
|
2013-04-02 |
2014-10-09 |
The Scripps Research Institute |
Uses of cyclic peptides for treating and preventing atherosclerosis
|
|
AU2014306002B2
(en)
|
2013-08-07 |
2017-05-25 |
Alexion Pharmaceuticals, Inc. |
Atypical hemolytic uremic syndrome (aHUS) biomarker proteins
|
|
EP3359555B1
(en)
|
2015-10-07 |
2023-12-20 |
Apellis Pharmaceuticals, Inc. |
Dosing regimens
|
|
US20190270778A1
(en)
|
2016-07-29 |
2019-09-05 |
Pfizer Inc. |
Cyclic Peptides As C5a Receptor Antagonists
|
|
US20200057046A1
(en)
|
2016-10-27 |
2020-02-20 |
Alexion Pharmaceuticals, Inc. |
Assay for c5b-9 deposition in complement-associated disorders
|
|
TWI826364B
(zh)
|
2017-04-03 |
2023-12-21 |
德商因夫萊亞斯有限公司 |
活性抑制劑於發炎性疾病之治療
|
|
US10376595B2
(en)
|
2017-04-03 |
2019-08-13 |
Inflarx Gmbh |
Treatment of inflammatory diseases with inhibitors of C5a activity
|
|
JP2020516607A
(ja)
|
2017-04-07 |
2020-06-11 |
アペリス・ファーマシューティカルズ・インコーポレイテッドＡｐｅｌｌｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． |
投与レジメンならびに関連組成物および方法
|
|
EP3642230A1
(en)
|
2017-06-23 |
2020-04-29 |
InflaRx GmbH |
Treatment of inflammatory diseases with inhibitors of c5a activity
|
|
AU2018386304B2
(en)
|
2017-12-15 |
2023-12-07 |
Apellis Pharmaceuticals, Inc. |
Dosing regimens and related compositions and methods
|
|
WO2021067526A1
(en)
|
2019-10-02 |
2021-04-08 |
Alexion Pharmaceuticals, Inc. |
Complement inhibitors for treating drug-induced complement-mediated response
|
|
EP4126222A1
(en)
|
2020-03-27 |
2023-02-08 |
InflaRx GmbH |
Inhibitors of c5a for the treatment of corona virus infection
|
|
TW202208427A
(zh)
|
2020-05-06 |
2022-03-01 |
德商因夫萊亞斯有限公司 |
人源化抗ｃ５ａ抗體
|
|
WO2021231720A1
(en)
|
2020-05-15 |
2021-11-18 |
Alexion Pharmaceuticals, Inc. |
Method of using extracellular vesicles to detect complement activation, and uses thereof to assess and/or monitor treatment of a complement-mediated disease
|
|
WO2024238422A1
(en)
|
2023-05-12 |
2024-11-21 |
Alexion Pharmaceuticals, Inc. |
Use of a panel of lectins for detection of complement biomarkers in urine extracellular vesicles
|
|
WO2024238421A1
(en)
|
2023-05-12 |
2024-11-21 |
Alexion Pharmaceuticals, Inc. |
Use of biomarkers for the identification and treatment of complement-mediated disorders
|
|
US12180274B2
(en)
|
2023-05-26 |
2024-12-31 |
Inflarx Gmbh |
Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity
|